Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 4Neoplasms 3Lymphoma, T-Cell, Peripheral 3Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, B-Cell 2Recurrence 1Neoplasms by Histologic Type 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lymphatic Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

10-propargyl-10-deazaaminopterin 6Brentuximab Vedotin 5romidepsin 3Vitamin B 12 3Rituximab 3Folic Acid 3Cyclophosphamide 3tenalisib 2cobomarsen 2belinostat 2Vincristine 2Prednisone 2Gemcitabine 2Doxorubicin 2zanubrutinib 1zanolimumab 1venetoclax 1tislelizumab 1quisinostat 1pembrolizumab 1mogamulizumab 1fostamatinib 1forodesine 1fludarabine 1enzastaurin 1enzalutamide 1duvelisib 1denileukin diftitox 1darinaparsin 1cc-486 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, T-Cell × denileukin diftitox × Clear all
NCT00211198 2008-03-05

Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

Eisai Inc.

Phase 4 Completed
60 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡